治疗家族性高胆固醇血症：坚持持续治疗。 - Suppr

Suppr

超能文献

Treating Familial Hypercholesterolemia: An Insistence on Persistence.

作者信息

Spitz Jared A

机构信息

Inova Schar Heart and Vascular, Fairfax, Virginia, USA.

出版信息

JACC Case Rep. 2024 Dec 4;29(23):102739. doi: 10.1016/j.jaccas.2024.102739.

DOI:10.1016/j.jaccas.2024.102739

PMID:39691326

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11646865/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51bd/11646865/b0c29a73264d/ga1.jpg

相似文献

Treating Familial Hypercholesterolemia: An Insistence on Persistence.治疗家族性高胆固醇血症：坚持持续治疗。

JACC Case Rep. 2024 Dec 4;29(23):102739. doi: 10.1016/j.jaccas.2024.102739.

Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.高胆固醇血症的管理、高心血管风险患者治疗方法的适宜性及新药

High Blood Press Cardiovasc Prev. 2016 Sep;23(3):217-30. doi: 10.1007/s40292-016-0155-2. Epub 2016 Aug 27.

[Unmet needs: patients with statin intolerance or familial hypercholesterolemia].未满足的需求：他汀类药物不耐受或家族性高胆固醇血症患者

Clin Investig Arterioscler. 2016 May;28 Suppl 2:22-30. doi: 10.1016/S0214-9168(16)30167-X.

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.阿利西尤单抗在非他汀类降脂治疗或最低强度他汀治疗未充分控制的高胆固醇血症患者中的疗效和安全性：ODYSSEY 日本研究设计与原理

Lipids Health Dis. 2017 Jun 17;16(1):121. doi: 10.1186/s12944-017-0513-7.

Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.意大利基于 AIFA 监测登记处的回顾性队列研究：PCSK9 抑制剂降低家族性高胆固醇血症患者 LDL-C 的真实世界疗效。

J Am Heart Assoc. 2023 Nov 7;12(21):e026550. doi: 10.1161/JAHA.122.026550. Epub 2023 Oct 18.

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.贝匹地酸治疗对高胆固醇血症患者的 3 期随机临床试验中致动脉粥样硬化脂质水平的影响。

JAMA Cardiol. 2020 Oct 1;5(10):1124-1135. doi: 10.1001/jamacardio.2020.2314.

Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?载脂蛋白 B 单克隆抗体在杂合子家族性高胆固醇血症合并心血管疾病中的应用：PCSK-9 抗体之后还有什么？

Eur J Prev Cardiol. 2017 Sep;24(14):1528-1531. doi: 10.1177/2047487317712419. Epub 2017 May 30.

Therapeutic Persistence in the Management of Familial Hypercholesterolemia: A Case of Acquired PCSK9 Inhibitor Nonresponse.家族性高胆固醇血症管理中的治疗持续性：一例获得性PCSK9抑制剂无反应病例

JACC Case Rep. 2024 Dec 4;29(23):102712. doi: 10.1016/j.jaccas.2024.102712.

Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.杂合子家族性高胆固醇血症患者他汀类药物治疗后的亚临床冠状动脉粥样硬化与心血管风险分层。

Curr Opin Lipidol. 2019 Apr;30(2):82-87. doi: 10.1097/MOL.0000000000000573.

The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia.非他汀类降脂药物在青少年高胆固醇血症中的作用。

Curr Atheroscler Rep. 2022 May;24(5):379-389. doi: 10.1007/s11883-022-01013-x. Epub 2022 Mar 28.

本文引用的文献

Exploring Barriers and Facilitators to Indirect Cascade Screening for Familial Hypercholesteraemia in a Paediatric/Parent Population.探索儿科/家长群体中家族性高胆固醇血症间接级联筛查的障碍与促进因素。

CJC Pediatr Congenit Heart Dis. 2023 May 29;2(5):211-218. doi: 10.1016/j.cjcpc.2023.05.006. eCollection 2023 Oct.

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia.国际动脉粥样硬化学会家族性高胆固醇血症管理最佳实践实施指南。

Nat Rev Cardiol. 2023 Dec;20(12):845-869. doi: 10.1038/s41569-023-00892-0. Epub 2023 Jun 15.

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study.2020年至2021年欧洲高危和极高危患者低密度脂蛋白胆固醇控制实施中的治疗差距：多国观察性圣托里尼研究

Lancet Reg Health Eur. 2023 Apr 5;29:100624. doi: 10.1016/j.lanepe.2023.100624. eCollection 2023 Jun.

2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.2022年美国心脏病学会解决方案集监督委员会关于非他汀类疗法在降低低密度脂蛋白胆固醇以管理动脉粥样硬化性心血管疾病风险中的作用的专家共识决策路径报告。

J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418. doi: 10.1016/j.jacc.2022.07.006. Epub 2022 Aug 25.

Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: A 2019 update.美国动脉粥样硬化性心血管疾病患者的血脂治疗现状与目标达成情况：2019年更新

Am J Prev Cardiol. 2022 Mar 20;10:100336. doi: 10.1016/j.ajpc.2022.100336. eCollection 2022 Jun.

Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care.他汀类药物治疗及家族性高胆固醇血症患者在初级保健中的 LDL-胆固醇治疗目标达标情况。

Open Heart. 2021 Oct;8(2). doi: 10.1136/openhrt-2021-001817.

Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US.在美国动脉粥样硬化性心血管疾病患者登记库GOULD中，降脂疗法两年以上的使用情况。

JAMA Cardiol. 2021 Sep 1;6(9):1060-1068. doi: 10.1001/jamacardio.2021.1810.

New Case Detection by Cascade Testing in Familial Hypercholesterolemia: A Systematic Review of the Literature.家族性高胆固醇血症中级联检测的新病例检出：文献系统评价。

Circ Genom Precis Med. 2019 Nov;12(11):e002723. doi: 10.1161/CIRCGEN.119.002723. Epub 2019 Oct 22.

Therapeutic Inertia in Cardiovascular Disease Prevention: Time to Move the Bar.心血管疾病预防中的治疗惰性：是时候提高标准了。

J Am Coll Cardiol. 2019 Oct 1;74(13):1728-1731. doi: 10.1016/j.jacc.2019.08.014.

Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction.青年心肌梗死患者中的家族性高胆固醇血症。

J Am Coll Cardiol. 2019 May 21;73(19):2439-2450. doi: 10.1016/j.jacc.2019.02.059.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验